Hematopoietic Cell Transplantation in Children with Sickle Cell Disease: A Single-Center Experience and Exploration of an Age Threshold for Post-Transplant Complications

Background/Objectives: Hematopoietic cell transplantation (HCT) is the only established curative option for sickle cell disease (SCD), yet the optimal timing in pediatric cohorts remains incompletely defined.

Methods

We retrospectively analyzed all patients under 20 years with SCD who underwent HCT at the University Hospital of Strasbourg between 2006 and 2024 and explored whether an age threshold exists for post-HCT complications.